Heart failure is a global pandemic with an estimated 64.3 million cases worldwide in 2017, costing over US$100B per year. Drug developers currently lack effective humanized models for preclinical testing of targeted drug candidates in heart failure with preserved ejection fraction. The collaboration aims to provide a unique solution for future assessment of novel therapeutics.
27 November, 2019
Accurate and detailed protein interactions analysis under near-native conditions with an easy-to-use system
19 November, 2019
SOMERSET, N.J. – November 4, 2019 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced the launch of its next-generation cell line development technology, GPEx® Boost.
07 November, 2019
• Integration of PAA’s S-LAB with Sphere Fluidics’ Cyto-Mine Single Cell Analysis System increases throughput in antibody discovery and cell line development• Launch at ELRIG Drug Discovery 2019, 5–6 November, Liverpool
06 November, 2019
This innovative new feature will further support the preclinical development of precision cancer therapies
05 November, 2019